PAREXEL EXPANDS ALLIANCE NETWORK TO SUPPORT EARLY PHASE PATIENT STUDIES, ESTABLISHES COLLABORATION WITH UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST
Boston, MA, January 23, 2012—PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has established an alliance with University Hospitals Bristol National Health Service (NHS) Foundation Trust (UH Bristol), one of the largest specialist teaching and research hospital trusts in the United Kingdom. Through this agreement with UH Bristol, PAREXEL continues to expand its alliance network, which complements its dedicated team of experts and hospital-based Early Phase units, providing clients with access to diverse patient populations worldwide in key therapeutic areas.
“Our extensive, relevant experience and in-depth expertise, as well as global access to suitable patient populations, all contribute to our ability to assist clients with ever more complex early-phase trial design and execution. In doing so, our focus is to provide more efficient delivery of better, faster go/no-go decisions,” said Sy Pretorius, M.D., M.S., M.B.A., Corporate Vice President and Worldwide Head of Early Phase. “UH Bristol is an ideal alliance for us because of its experience in conducting clinical research, access to substantial patient populations, and work across multiple therapeutic areas.”
Research Director at UH Bristol Professor David Wynick said: “We believe this alliance furthers our objectives to develop collaborative and consultative research partnerships and support research of national and international excellence and innovation. We look forward to working with PAREXEL to expand our research portfolio for the benefit of patients.”
UH Bristol, the region’s largest provider of medical and dental teaching, is a leading research center and one of the largest acute NHS Trusts in the country. It employs over 7,900 people, and delivers over 100 different clinical services from a group of nine hospitals in the heart of the city.
With extensive, relevant experience and in-depth expertise, PAREXEL assists clients with ever more complex early-phase trial design and execution from First-in-Human (FIH) through Proof-of-Concept. The Company’s hospital-based units in the U.S., Europe, and South Africa, as well as a network of alliance sites, provide clients with excellent patient access specific to key therapeutic areas for early phase development. For more information about PAREXEL's early phase development capabilities visit: http://www.parexel.com/services-and-capabilities/early-phase.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 67 locations throughout 52 countries around the world, and has approximately 10,850 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged